Growth Hormone Therapy in Chronic Heart Failure: a Systematic Review and Meta-Analysis of Randomized Controlled Trials
Context
Guideline-directed medical therapy of heart failure (HF) primarily targets neurohormonal activation. However, growth hormone (GH) has emerged as a potential treatment for the multiple hormonal deficiency syndrome, which is associated with worse outcomes in HF.
Objective
This study evaluates the efficacy and safety of GH therapy in HF.
Data Sources
A systematic search was conducted in PubMed, Cochrane Library, and ClinicalTrials.gov, according to PRISMA guidelines
Study Selection
Randomized, placebo-controlled trials studying GH therapy in adult HF patients were included. Of the 1,184 initially identified records, 17 studies (1.4%) met the inclusion criteria.
Data extraction
Two independent authors conducted the search, with any disagreements resolved by a third author. Study quality was assessed using predefined criteria, including randomization, blinding, and the presence of a placebo group.
Data Synthesis
A random-effects model was applied due to heterogeneity across studies. GH therapy significantly improved left ventricular ejection fraction (3.34%, 95% CI: 1.09% to 5.59%, p=0.0037), peak oxygen consumption (2.84 mL/kg/min, 95% CI: 1.32 mL/kg/min to 4.36 mL/kg/min, p=0.0002), and New York Heart Association class (-0.44, 95% CI: -0.08 to -0.81, p=0.023). GH therapy also reduced the composite of death, worsening HF or ventricular tachycardia by 41% (95% CI: 0.39-0.90, p=0.013). Subgroup analyses indicated that patients with ischemic cardiomyopathy, baseline ejection fraction ≥30% and longer treatment duration experienced greater benefits.
Conclusions
GH therapy may improve cardiac function, exercise capacity, and HF symptoms, with a trend towards improvement in hard endpoints, such as worsening HF. Event-driven trials are necessary to validate these findings.
Top-30
Journals
|
1
2
|
|
|
Diagnostics
2 publications, 14.29%
|
|
|
Biomolecules
2 publications, 14.29%
|
|
|
International Journal of Molecular Sciences
1 publication, 7.14%
|
|
|
Biomedicines
1 publication, 7.14%
|
|
|
Clinical Endocrinology
1 publication, 7.14%
|
|
|
Nutrients
1 publication, 7.14%
|
|
|
Heart Failure Reviews
1 publication, 7.14%
|
|
|
JACC: Heart Failure
1 publication, 7.14%
|
|
|
Hormones
1 publication, 7.14%
|
|
|
Journal of Clinical Endocrinology and Metabolism
1 publication, 7.14%
|
|
|
Pharmacognosy Magazine
1 publication, 7.14%
|
|
|
1
2
|
Publishers
|
1
2
3
4
5
6
7
|
|
|
MDPI
7 publications, 50%
|
|
|
Springer Nature
2 publications, 14.29%
|
|
|
Wiley
1 publication, 7.14%
|
|
|
Elsevier
1 publication, 7.14%
|
|
|
The Endocrine Society
1 publication, 7.14%
|
|
|
IGI Global
1 publication, 7.14%
|
|
|
Medknow
1 publication, 7.14%
|
|
|
1
2
3
4
5
6
7
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.